Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.55 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19175780 | 0.99 | ALDH1A1 (0.61) | ALDH1A1HPGDPKMKDM4ESMN1; SMN2 | |
| SCHEMBL19137926 | 0.88 | AURKA (0.56) | ALDH1A1HPGDPKMKDM4ESMN1; SMN2 | |
| SCHEMBL19137960 | 0.87 | DGAT1 (0.60) | ALDH1A1HPGDPKMKDM4ESMN1; SMN2 | |
| SCHEMBL19198151 | 0.76 | SIRT2 (0.59) | ALDH1A1HPGDSMN1; SMN2AURKANPBWR1 | |
| SCHEMBL19137947 | 0.76 | CCR2 (0.58) | ALDH1A1HPGDSMN1; SMN2AURKANPBWR1 | |
| SCHEMBL24075401 | 0.76 | NPBWR1 (0.58) | ALDH1A1HPGDKDM4ESMN1; SMN2AURKA | |
| SCHEMBL3672172 | 0.75 | ALDH1A1 (0.49) | ALDH1A1HPGDPKMKDM4ESMN1; SMN2 | |
| SCHEMBL3672168 | 0.75 | ALDH1A1 (0.49) | ALDH1A1HPGDPKMKDM4ESMN1; SMN2 | |
| SCHEMBL9694046 | 0.75 | ALDH1A1 (1.00) | ALDH1A1HPGDPKMKDM4ESMN1; SMN2 | |
| SCHEMBL21565901 | 0.75 | ALDH1A1 (0.71) | ALDH1A1HPGDPKMKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017132511-A1 | BENZIMIDAZOLE COMPOUNDS, USE AS INHIBITORS OF WNT SIGNALING PATHWAY IN CANCERS, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170210741-A1 | Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof | SOUTHERN RESEARCH INSTITUTE | 2017-07-27 | — | — | US | disclosed |
| US-20170210741-A1 | Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof | SOUTHERN RESEARCH INSTITUTE | 2017-07-27 | — | — | US | disclosed |
| US-20170210741-A1 | Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof | SOUTHERN RESEARCH INSTITUTE | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210741-A1 | Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof | WNT1, WNT3, CTNNB1 | ALDH1A1 1257/4885HPGD 2366/4885PKM 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.